Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently needed. Toward this end, we performed a comprehensive genetic analysis of 24 pancreatic cancers. We first determined the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, in these samples. Then, we searched for homozygous deletions and amplifications in the tumor DNA by using microarrays containing probes for ∼106 single-nucleotide polymorphisms. We found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations. These alterations defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors. Analysis of these tumors' transcriptomes with next-generation sequencing-by-synthesis technologies provided independent evidence for the importance of these pathways and processes. Our data indicate that genetically altered core pathways and regulatory processes only become evident once the coding regions of the genome are analyzed in depth. Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis.

[1]  K. Kinzler,et al.  Serial Analysis of Gene Expression , 1995, Science.

[2]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[3]  A. Hartmann,et al.  The molecular epidemiology of p53 gene mutations in human breast cancer. , 1997, Trends in genetics : TIG.

[4]  C. Harris,et al.  p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. , 1999, Mutation research.

[5]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[6]  M. Tsao,et al.  Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. , 2000, The American journal of pathology.

[7]  N. Lemoine,et al.  Pancreatic Cancer Genetics , 2001, Pancreatology.

[8]  Scott E Kern,et al.  Focus on pancreas cancer. , 2002, Cancer cell.

[9]  R. Hruban,et al.  Direct Correlation between Proliferative Activity and Dysplasia in Pancreatic Intraepithelial Neoplasia (PanIN): Additional Evidence for a Recently Proposed Model of Progression , 2002, Modern Pathology.

[10]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[11]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[12]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[13]  R. Hruban,et al.  Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion , 2005, Modern Pathology.

[14]  M. Mimeault,et al.  Recent Advances on the Molecular Mechanisms Involved in Pancreatic Cancer Progression and Therapies , 2005, Pancreas.

[15]  D. Tuveson,et al.  Ductal pancreatic cancer in humans and mice. , 2005, Cold Spring Harbor symposia on quantitative biology.

[16]  M. Stratton,et al.  Statistical Analysis of Pathogenicity of Somatic Mutations in Cancer , 2006, Genetics.

[17]  R. Hruban,et al.  An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.

[18]  S. Kern,et al.  Multiple-criterion evaluation of reported mutations: A proposed scoring system for the intragenic somatic mutation literature , 2006, Cancer biology & therapy.

[19]  Sean Ekins,et al.  Pathway mapping tools for analysis of high content data. , 2007, Methods in molecular biology.

[20]  A. Varshavsky Targeting the absence: Homozygous DNA deletions as immutable signposts for cancer therapy , 2007, Proceedings of the National Academy of Sciences.

[21]  G. Parmigiani,et al.  A multidimensional analysis of genes mutated in breast and colorectal cancers. , 2007, Genome research.

[22]  Ryan D. Morin,et al.  Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. , 2008, BioTechniques.

[23]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[24]  John Quackenbush,et al.  Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. , 2008, Genomics.

[25]  R. Lister,et al.  Highly Integrated Single-Base Resolution Maps of the Epigenome in Arabidopsis , 2008, Cell.

[26]  Sayan Mukherjee,et al.  Modeling Cancer Progression via Pathway Dependencies , 2008, PLoS Comput. Biol..

[27]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[28]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[29]  Marcel H. Schulz,et al.  A Global View of Gene Activity and Alternative Splicing by Deep Sequencing of the Human Transcriptome , 2008, Science.

[30]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.